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Located along Philadelphia’s Main Line in 
Wynnewood, Pa., the Lankenau Institute 
for Medical Research (LIMR) aims to 
advance health and well-being through 
research to improve the detection and 
treatment of disease; the rapid transfer 
of new technology to the clinic; and 
the training of the next generation of 
scientists and physicians. 
Founded in 1927, LIMR now has a 
team of 120 – including 20 resident 
faculty members – working to advance 
its mission. Those investigators include 
LIMR President and CEO George C. 
Prendergast, PhD, who also serves as 
editor in chief of Cancer Research, the 
most highly cited journal in the field, 
and Janet Sawicki, PhD, Professor, whose 
work focuses on cancer nanotherapy  
and related technologies.
In recent years, Drs. Prendergast 
and Sawicki have been collaborating 
successfully with the Jefferson Department 
of Surgery on research related to 
diagnosis and treatment of pancreatic 
and ovarian cancers. As Jonathan Brody, 
PhD, Director of the Division of Surgical 
Research recalls, the relationship took 
root in 2007, when Dr. Sawicki delivered a 
presentation on cancer nanotherapy at the 
monthly Surgical Research Seminar hosted 
by the Division. 
Since then, Jefferson and LIMR have 
co-authored multiple publications and 
secured four nationally recognized  
grants (including from NIH and the 
American Cancer Society) worth roughly 
a million dollars. 
The grants have funded research on 
predicting and optimizing the effect 
of gemcitabine therapy in ovarian and 
pancreatic cancers; using the HuR stress 
response gene to enhance Gemcitabine 
therapy; using HuR to combat 
chemotherapeutic resistance in ovarian 
cancer; and IDO2 targeting for pancreatic 
cancer treatment. Early work seeding 
the IDO2 collaboration was published 
initially by the Jefferson-LIMR team in 
the Journal of the American College of 
Surgery in 2009. 
“Both these collaborations are unique 
and allow us to attack these tumors with 
different strategies,” Dr. Brody says. 
“Drs. Prendergast and Sawicki are the 
only people in the world I could do this 
particular work with, and luckily, they are 
in our backyard.”
The collaboration has been beneficial to 
the researchers at LIMR, as well: “I met 
Dr. Brody not long after he moved to 
Jefferson from Johns Hopkins with Dr. 
Charlie Yeo’s team, when we were each 
just beginning to become interested in 
how IDO2 may affect cancer,” recalls  
Dr. Prendergast. “We had discovered this 
gene as a result of our work in cancer 
immunotherapy, but its connections to 
pancreatic cancer would not have been 
made so soon without Dr. Brody’s initial 
observation that brought us together.” 
Dr. Sawicki feels similarly about the 
interactions that started with the seminar 
at Jefferson: “Jonathan and I quickly 
identified a few high-impact questions 
of common interest where our research 
programs could readily benefit from 
collaborative work,” she said. “We were 
fortunate that the multidisciplinary 
synergies in the work we started were 
welcomed so readily by the grant 
review committees who have made its 
development possible. 
“For me, the ability to benefit from access 
to clinical specimens and linked databases 
was critical, given that few groups have 
assembled such a valuable foundation 
to enable research into the questions I 
wished to pursue.” 
Jefferson and LIMR are currently preparing 
two grants for roughly $1.25 million each 
from the NIH Research Project Grant 
Program (R01). If awarded, these grants 
will fund research targeting HuR and IDO 
molecules for the treatment of pancreatic 
cancer and ovarian cancers – which all 
three investigators hope will be translated 
to the clinic within the next few years.
For more information about the Division of Surgical 
Research visit: www.jefferson.edu/surgery
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Chuck Rowland, MSN, CRNP
Chuck Rowland, MSN, CRNP, first came 
to Jefferson in 1986 as a newly graduated 
clinical perfusionist. Over the next 25 
years, he worked in several states and 
returned to Jefferson as a perfusionist 
before pursuing a career in nursing. In 
2007, he completed his BSN in Villanova 
University’s accelerated nursing program 
and continued his studies to earn his MSN 
as an Adult Nurse Practitioner in 2010. 
Since April 2011, Rowland has been 
supporting Jefferson’s Division of 
Cardiothoracic Surgery as an outpatient 
nurse practitioner. More recently, he 
assumed additional responsibilities 
as director of the Smoking Cessation, 
Counseling and Therapy (SCCT) Program, 
for which he became a Certified Tobacco 
Treatment Specialist.
What is the SCCT Program?
The SCCT Program is a relatively new 
endeavor that began with the progressive 
ideas and support of Scott Cowan, MD, 
FACS, one of our thoracic surgeons. The 
program’s goal is to jumpstart smoking 
cessation prior to surgery. During the 
appointment process, we screen all 
patients for smoking. If the patient agrees, 
we schedule him or her for a separate 
appointment for smoking cessation planning.
We’ve designed the SCCT Program to 
provide one-on-one counseling tailored 
to individual patient needs. Each smoking 
cessation plan of care is formulated with 
patient input. For most patients, the goal 
is to quit smoking over a period of a few 
weeks – and then sustain that success  
over the long term.
What is your philosophy of patient care?
Patients are multidimensional. When they 
come to us with physical issues, they 
also bring social, cultural and spiritual 
dimensions. I believe it’s important to 
formulate a plan of care that incorporates 
and adapts to these needs. 
What most energizes you about  
your career?
I’m energized by the ability to help patients 
navigate through their journey with 
cardiothoracic surgery and/or smoking 
cessation, which for most is a very stressful 
time. I always strive to help patients and 
their families truly understand what’s 
happening – from admission through final 
discharge and even weeks after surgery. 
Learn more at: www.jeffersonhospital.org/SCCT
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“ Drs. Prendergast and Sawicki 
are the only people in the world 
I could do this particular work 
with, and luckily, they are in 
our backyard.”
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